Skip to content

Effect of artificial intelligence-assisted Baduanjin training on the active health management ability of patients with hypertension

Effect of artificial intelligence-assisted Baduanjin training on the active health management ability of patients with hypertension

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500106306
Enrollment
Unknown
Registered
2025-07-22
Start date
2024-09-03
Completion date
Unknown
Last updated
2025-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension

Interventions

Baduanjin online AI-assisted exercise intervention group:Baduanjin training based on artificial intelligence assistance
Baduanjin exercise intervention group:Baduanjin training based on artificial intelligence assistance

Sponsors

Zhujiang Hospital of Southern Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Voluntarily participate in the trial and sign the informed consent form; 2. Age 18-70 years old; 3. Have passed the physical activity preparation questionnaire screening or approved by a physician before participating; 4. Be able to communicate normally and cooperate with questionnaires; 5. Do not participate in other related studies involving the promotion of healthy lifestyle (physical exercise); 6. Have a smartphone and be able to access WeChat and the Internet through your smartphone. 7. Meet the diagnostic criteria for hypertension in the 2018 Revision of the Chinese Guidelines for the Prevention and Treatment of Hypertension, systolic blood pressure >=140 mmHg and/or diastolic blood pressure >=90 mmHg, and be diagnosed with hypertension.

Exclusion criteria

Exclusion criteria: 1. Patients with secondary hypertension; 2. Patients with severe or hypertension whose blood pressure is not effectively controlled (i.e., resting SBP>=180mmHg and/or) DBP>=110mmHg; 3. Patients with pulmonary hypertension, severe hypertension, hypertensive crisis, unstable stage III hypertension, hypertensive encephalopathy or rapidly progressive hypertension, or other serious complications, such as severe arrhythmias, tachycardia, heart failure, unstable angina, and obvious adverse reactions of antihypertensive drugs that cannot be controlled; 4. Patients with malignant tumors or hypertension with left ventricular ejection fraction less than 55%, combined with aortic valve, mitral valve, tricuspid valve, pulmonary artery stenosis, mitral valve, tricuspid valve, pulmonary valve severe regurgitation, hypertrophic cardiomyopathy, acute infection, fundus hemorrhage, diabetic acidosis, lower limb gangrene, severe hypothyroidism, renal insufficiency. 5. Accompanied by injury to motor organs, bone and joint surgery < 1 year, such as hip and knee replacement surgery, spine surgery, etc. 6. Unable to understand or answer questions or complete questionnaires due to subjective or objective reasons; 7. Those who are not suitable to participate in clinical trials in the opinion of the investigator.

Design outcomes

Primary

MeasureTime frame
Hypertension self-management skills;Chronic disease self-efficacy;

Secondary

MeasureTime frame
Quality of life scale scores;BMI;Timed Up and Go Test;Waist-to-hip ratio;Generalized Anxiety Disorder Scale;Six-minute walk test;Blood pressure;Montreal Cognitive Assessment;Depression Symptom Scale;Static balance test;Grip strength;Sleep Quality in Pittsburgh;30-second sit-stand test;

Countries

China

Contacts

Public ContactGuozhi Huang

Zhujiang Hospital of Southern Medical University

drhuang66@163.com+86 20 6278 2771

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026